MDMA — Pharmala Biotech Holdings Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$10.48m
- CA$10.44m
- CA$0.53m
2021 August 31st | 2022 August 31st | 2023 August 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Net Income/Starting Line | -2.51 | -0.986 | -0.78 |
Depreciation | |||
Non-Cash Items | 2.23 | 0.237 | 0.011 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | 0.109 | 0.112 | 0.377 |
Change in Accounts Receivable | |||
Change in Inventories | |||
Change in Prepaid Expenses | |||
Change in Payable / Accrued Expenses | |||
Change in Other Liabilities | |||
Cash from Operating Activities | -0.174 | -0.625 | -0.34 |
Capital Expenditures | -0.262 | -0.995 | -0.507 |
Purchase of Fixed Assets | |||
Software Development Costs | |||
Other Investing Cash Flow Items | 0.891 | 0 | — |
Sale of Business | |||
Cash from Investing Activities | 0.629 | -0.995 | -0.507 |
Net Issuance / Retirement of Stock | |||
Cash from Financing Activities | 2.02 | 0 | 0.189 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | 2.47 | -1.62 | -0.657 |